Clinical Trial

HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Patients with unresectable HCC will be enrolled in the cohort and will receive the combination therapy of HAIC and atezolizumab plus bevacizumab. The objective response rate is the primary endpoint, and the secondary endpoint includes disease control rate, conversion rate, pathologic complete response, major pathologic response, progression-free survival, recurrence-free survival, overall survival, quality of life, and safety.
Trial Details
NCT Number NCT07045558
Lead Sponsor RenJi Hospital
Conditions Unresectable Hepatocellular Carcinoma
Enrollment 28 participants
Start Date 2025-08-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-01